Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Phase III, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease (NILEAD)

Next Previous
X
Search
Trial Profile

A Multicenter, Phase III, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease (NILEAD)

Status: Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nilotinib (Primary)
  • Indications Alzheimer's disease; Dementia
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms NILEAD
  • Sponsors KeifeRx

    • Most Recent Events

    • 08 Dec 2021 According to a KeifeRx media release, this study is expected to initiate in early 2022.
    • 27 Jul 2021 According to a KeifeRx media release, the company has received an acceptance of its Investigational New Drug (IND) application from the United States Food and Drug Administration (FDA) to launch a phase III trial for Nilotinib BE.
    • 27 Jul 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top